Development of Cancer Medicines:

in association with Royal Society of Medicine Section of Oncology

Venue:
Royal Society of Medicine, London
Starts:
29th November 2012 at 7:00am

Preclinical in vivo models to interrogate cancer biology, biomarkers and therapeutic response.

What are the latest advances in preclinical in vivo modelling? 

How can models be used to reveal cancer targets, develop clinically translatable biomarkers or assess therapeutic response meaningfully?

The main purpose of this event is to bring together experts in the field of modelling cancer biology in vivo, to hear about and discuss recent advances in the use of such models to inform target identification, therapeutic testing and biomarker development.

In covering basic and translational science, the meeting will be of wide interest to preclinical scientists and clinicians, from academia or industry. This interactive day will provide a unique opportunity to share experiences and perspectives, through a series of invited talks, a poster session, short poster-discussion presentations and a round-table debate.

Abstract Submission opens 1st July 2012

Confirmed Speakers:

  • Johannes Zuber (Vienna)
  • Thorsten Hagemann (London)
  • Matt Smalley (Cardiff)
  • Manuel Hildago (Madrid)
  • Kevin Brindle (Cambridge)
  • Hing Leung (Glasgow)

We will be offering poster prizes to students and opportunities for postdocs and student to present their research through selected orgal presentations

Organising Committee:

  • Steve Wedge (AstraZeneca)
  • Val Brunton (Cancer Research Centre, Edinburgh)
  • Owen Sansom (Beatson Reesearch Centre, Glasgow